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InTroduCTIon
Aortic stenosis (AS) is the most common valve 
disease requiring surgical intervention in high-in-
come countries.1 It is characterised by progressive 
thickening, fibrosis and calcification of the leaf-
lets leading to restriction and valve obstruction.2 
The consequent increase in left ventricular after-
load leads to a hypertrophic response of the left 
ventricle, normalising wall tension and maintaining 
cardiac output. However, with progressive valvular 
stenosis, this hypertrophic response eventually 
decompensates resulting in symptom development, 
heart failure and death.
With no medications proven to attenuate or 
reverse stenosis progression, the only available 
treatment is valve replacement. This should ideally 
be performed when the risks of the disease process 
(ie, sudden cardiac death, irreversible functional 
impairment and heart failure) outweigh those 
of intervention (ie, procedural risk, long-term 
complications and potential need for reoperation). 
However, we frequently lack robust evidence to 
make accurate assessments of such risk. Deciding 
on the timing of valvular intervention is therefore 
difficult in many patients, and contemporary clin-
ical guidelines are often underpinned by histor-
ical observational data rather than high-quality 
randomised controlled trials. This article will review 
our current understanding of the pathophysiology 
of AS, describe and examine the evidence behind 
current guideline recommendations and explore 
potential future strategies to optimise the timing of 
valve intervention.
PaTHoPHysIology of valvular sTEnosIs 
and THE HyPErTroPHIC rEsPonsE
Since the original description of AS by Mönckeberg 
in 1904, the decline in rheumatic fever and ageing 
population have led to a demographic transition 
towards fibrocalcific disease. For many years, fibro-
calcific AS was viewed as a degenerative disease 
where progressive ‘wear and tear’ led to struc-
tural damage and passive valvular calcification. 
However, contemporary thinking is that fibrocal-
cific AS develops as part of a series of intricate and 
highly regulated inflammatory, fibrotic and osteo-
genic processes. The pathophysiological processes 
driving aortic valve stenosis can be divided into 
two phases.2 The initiation phase is characterised 
by endothelial injury accompanied by infiltration 
of lipids, lipid oxidation and proinflammatory 
response. Despite the clear similarities with athero-
sclerosis, three large randomised trials have failed 
to show any effect of statins on disease progression 
or clinical outcome. The propagation phase is char-
acterised by the appearance of osteoblast-like cells 
that coordinate progressive valvular calcium and 
bone matrix deposition. This osteogenic pheno-
type involves many signalling molecules involved in 
bone formation and is both self-perpetuating and 
highly regulated.2 Advances in imaging now allow 
for non-invasive assessment of both the burden and 
activity of calcification in the valve3 4; however, 
the severity of aortic valve obstruction is still best 
assessed using echocardiography.5
Myocardial response
The traditional focus of AS assessments has been on 
the valve. However, the left ventricular myocardial 
response to pressure overload is equally important,6 
particularly as the correlation between echocardio-
graphic measures of AS severity and the degree of 
myocardial hypertrophy is moderate at best.7 While 
left ventricular hypertrophy maintains wall stress 
and cardiac output for many years, it eventually 
decompensates, with cell death and myocardial 
fibrosis identified as key processes.8 Many imaging 
and biomarker surrogates of these processes have 
been investigated providing significant prog-
nostic information that will be discussed later in 
this article. Gender appears to have an important 
influence on both the LV remodelling response 
and patient outcomes,9 but detailed discussion is 
beyond the scope of this article.
CurrEnT guIdElInE-rECoMMEndEd 
TrEaTMEnT sTraTEgIEs and THEIr 
lIMITaTIons
Broadly speaking, contemporary clinical guide-
lines recommend aortic valve intervention when 
stenosis severity is deemed severe and there is 
evidence of left ventricular decompensation, using 
either direct objective or surrogate symptomatic 
learning objectives
 ► To review the pathophysiology of fibrocalcific 
aortic stenosis, the myocardial response to 
pressure overload and current clinical guidelines 
concerning the timing of valve intervention.
 ► To explore and to quantify the risks of earlier 
intervention in asymptomatic patients 
compared with the risks of a watchful waiting 
strategy.
 ► To detail future potential strategies for deciding 
on timing of aortic valve intervention and 
current ongoing randomised controlled trials.
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measures (figure 1 and table 1).10 11 Haemodynamic 
severity is best assessed using echocardiography but 
can be challenging when measures of severity are 
discordant or low-flow states exist. New recom-
mendations for confirming AS severity are given in 
the 2017 ESC/EACTS guideline update.5 Detailed 
discussion of low-flow states is beyond the scope of 
this article but can be found elsewhere.12
Presence of as-related symptoms
It is universally accepted that the development of 
patient symptoms (exertional dyspnoea, angina 
or syncope; table 2) serves as an indicator of left 
ventricular decompensation and a dismal prognosis 
without intervention. This was first described in the 
seminal paper by Braunwald and Ross in 196813 and 
forms the underlying framework of how we manage 
patients today. However, this finding was based 
on retrospective data from just 12 patients with a 
mixture of bicuspid and rheumatic valve disease 
and a mean age of death of 63 years. The changing 
demographics of AS make it difficult to interpret 
the current relevance of these historical data to the 
patients seen in current practice who are frequently 
in their eighth or ninth decades. Symptom assess-
ment can be highly challenging in these patients due 
to the high prevalence of both comorbidity, which 
may cause symptoms to be falsely attributed to AS, 
and physical inactivity, which can conceal exer-
tion-related problems.
Exercise testing may help unmask symptoms in 
many patients and is safe when performed in stable 
patients.14 ESC guidelines recommend surgery in 
patients with severe ASand typical symptoms on 
exercise test (class I, level C) or a fall in systolic 
blood pressure at peak exercise (class IIa, level C). 
This recommendation is based largely on obser-
vational data demonstrating that a positive exer-
cise test is a strong predictor of sudden death or 
symptom development.15 However, these data are 
limited, consisting of a series of relatively small 
observational studies with inherent risk of bias and 
figure 1 ESC/EACTS algorithm for management of severe AS (2017 guidelines). AS, aortic stenosis; LVEF, left ventricular ejection fraction; 
SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.
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heterogeneity as to what constituted an abnormal 
test. According to a recent meta-analysis, while 
the negative predictive value of stress testing for 
subsequent cardiac events is reasonable (79%), 
the positive predictive value is modest (66%).14 
Exercise testing has other major limitations; up 
to 20% of patients will be unable to perform the 
test due to poor mobility, while pre-existing ECG 
abnormalities are present in up to 50% of patients 
confounding test interpretation.16 It is worth noting 
that exercise testing may also detect abnormalities 
caused by coexistent coronary disease, which is an 
important determinant of both management and 
prognosis.17
Impaired left ventricular ejection fraction
Development of left ventricular systolic impairment, 
as identified by a reduced left ventricular ejection 
fraction, is an inevitable consequence of progressive 
and untreated valvular stenosis assuming sudden 
death does not occur. Although the risk of perioper-
ative mortality is elevated in the setting of reduced 
ejection fraction, these patients have a dismal prog-
nosis without intervention and improved long-term 
outcomes with valve replacement earning a class I, 
level C recommendation in clinical guidelines.10 11
In clinical practice, patients with AS can develop 
a reduction in ejection fraction for a variety of 
reasons, and it remains important to consider the 
mechanism of this reduction and whether it is 
reversible. Reductions in ejection fraction occur as 
a direct response to increases in afterload and will 
reverse following valve replacement. By contrast, 
the ejection fraction does not improve in approxi-
mately 25% of patients10 11 18 19 who are more likely 
to remain symptomatic and who have adverse long-
term outcomes (twice as likely to die over 5 years 
follow-up).20 In these patients, persistent systolic 
dysfunction appears related to the development of 
irreversible scar due to either myocardial infarction 
or decompensation of the hypertrophic response.21 
In sick, frail patients, such information may govern 
whether valve intervention is likely to be of benefit.
Reductions in ejection fraction are therefore a 
late, non-specific and often irreversible feature in 
AS, leading to interest in alternative methods for 
detecting left ventricular decompensation7 22–24 as 
will be discussed.
very severe as
Patients with critical AS appear to have a particu-
larly poor prognosis, similar to that of symptomatic 
Table 1 Recommendations for Intervention in patients with severe AS (ESC/EACTS guidelines 2017)
symptomatic severe as (surgical avr or TavI) Class Level
Indicated in severe high gradient AS (AV Vmax >4 m/s or mean gradient >40 mm Hg). I B
Indicated in patients with low-flow low-gradient severe AS with reduced ejection fraction and evidence of contractile reserve excluding pseudosevere 
AS.
I C
Should be considered in patients with low-flow low-gradient severe AS with preserved ejection fraction after careful confirmation of severe AS. IIa C
Should be considered in patients with low-flow low-gradient severe AS with reduced ejection fraction without evidence of contractile reserve 
especially where CT calcium scoring confirms severe AS.
IIa C
Should NOT be performed in patients with severe comorbidities where the intervention is unlikely to improve quality of life or survival. III C
asymptomatic severe as (surgical avr only)
Indicated in patients with severe AS and left ventricular systolic dysfunction (LVEF <50%) not due to another cause. I C
Indicated in patients with abnormal exercise test showing symptoms on exercise clearly related to AS. I C
Should be considered in patients with abnormal exercise test showing a decrease in blood pressure below baseline. IIa C
Should be considered if the surgical risk is low and one of the following abnormalities is present:
 ► Very severe AS (AV Vmax >5.5 m/s).
 ► Severe valve calcification with a rate of progression ≥0.3 m/s/year.
 ► Markedly elevated BNP (>3-fold above age-corrected and sex-corrected normal range) confirmed by repeated measurements without other 
explanations.
 ► Severe pulmonary hypertension (systolic pulmonary artery pressure >60 mm Hg at rest confirmed by invasive measurement) without other 
explanation.
IIa C
AS, aortic stenosis; AV, aortic valve; BNP, B-type natriuretic peptide; LVEF, left ventricular ejection fraction; TAVI, transcatheter aortic valve implantation.
Table 2 Symptomatology of severe aortic stenosis
symptom aetiology Potential questions to ask:
Angina Supply–demand imbalance: coexistent coronary disease and fixed 
cardiac output versus hypertrophied myocardium.
‘Do you get chest pain or discomfort when walking or doing other 
activities?’
Breathlessness/reduced exercise capacity Reduced LV compliance, increased left ventricular end-diastolic and 
pulmonary capillary pressures.
‘Can you walk ask many stairs as this time last year?’
‘Can you keep up with your friends?’
Presyncope/syncope
(important to elicit any exertional 
component)
Fixed cardiac output, skeletal muscle vasodilation on exertion and 
resultant cerebral hypoperfusion.
‘Have you felt lightheaded like you might faint?’ 
‘Have you had any fainting or blackout episodes?’
Palpitations Development of atrial or ventricular arrhythmia, myocardial 
scarring.
‘Are you aware of your heart racing?’
LV, left ventricular.
 o
n
 25 July 2018 by guest. Protected by copyright.
http://heart.bmj.com/
H
eart: first published as 10.1136/heartjnl-2017-312304 on 20 July 2018. Downloaded from 
4 Everett RJ, et al. Heart 2018;0:1–11. doi:10.1136/heartjnl-2017-312304
Education in Heart
severe AS.25 Indeed patients with peak aortic jet 
velocities of >5.0 and >5.5 m/s demonstrate a 
2-year event-free survival of 43% and 25%, respec-
tively, compared with 70% in those with Vmax 
4.0–4.9 m/s.26 The ESC/EACTS guidelines there-
fore recommend consideration of aortic valve 
replacement in patients with Vmax >5.5 m/s if 
the estimated surgical risk is low (class IIa, level 
C). However, these observational studies mostly 
examined the composite endpoint of mortality and 
referral for aortic valve intervention with a strong 
risk of referral bias and event rates mainly driven by 
decisions to perform surgery.
rapid haemodynamic progression
Although the average rate of progression (measured 
by peak aortic-jet velocity) is 0.24±0.30 m/s/
year, this rate is highly variable.27 Moreover, it is 
subject to scan–rescan variation in peak velocity 
measurements, which can be high in clinical prac-
tice. Patients with rapid progression (>0.3 m/s/
year) and significant valve calcification have a rate 
of symptom development or mortality of 79% at 2 
years.28 As a result, referral for surgical interven-
tion in these patients is given a class IIa, level C 
recommendation in the latest guidelines. However, 
again, this is based on limited observational data, 
and this strategy requires standardised high-quality 
echocardiography over several years to confidently 
determine rate of progression.
Elevation of B-type natriuretic peptide (BnP) 
levels
BNP is the first cardiac biomarker to be included 
in the decision-making algorithm for aortic valve 
replacement. Early studies investigating natri-
uretic peptides in AS showed promise but were 
criticised for their small size, observational nature 
and use of softer outcome endpoints.29 30 In 
addition, many patients were symptomatic, and 
the variation in normal BNP with age and sex 
were not accounted for. A more recent study of 
565 patients with asymptomatic moderate-to-se-
vere AS identified that a BNP ratio (measured 
BNP value divided by upper limit of normal for 
patient’s age and sex) of >1 was independently 
predictive of mortality and a ratio of >3 had an 
HR of 7.3 for survival in patients with asymp-
tomatic severe AS.31 As such, the latest clinical 
guidelines reflect these data with a level IIa, class 
C recommendation for aortic valve replacement if 
the BNP ratio is persistently above 3 and overall 
surgical risk is low. However, BNP is a non-spe-
cific marker of cardiac dysfunction, and its utility, 
like each of the other parameters, has yet to be 
tested in a randomised controlled trial.
The recently published ESC clinical guidelines 
also removed two previous IIb indications for AVR 
in asymptomatic patients: an increase in mean 
aortic gradient of >20 mm Hg with exercise, or the 
finding of excessive LV hypertrophy in the absence 
of hypertension.
BalanCIng CoMPETIng rIsks
There are clear limitations with many of our 
guideline-advocated strategies. Most are based on 
limited observational data and supported by level 
C recommendations. There is therefore a need for 
randomised controlled trials assessing the optimal 
timing of surgery and novel objective methods to 
guide this major clinical decision. Ideally, interven-
tion would be performed in patients just as the left 
ventricle is starting to decompensate but before 
substantial irreversible damage has accrued and at 
a time when the short-term and long-term risks of 
the intervention are outweighed by the risks of not 
intervening (figure 2 and table 3). An understanding 
of these competing risks is therefore critical.
figure 2 Optimising the timing of aortic valve intervention in progressive aortic stenosis. TAVI, transcatheter aortic valve insertion.
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risks of valve intervention
Surgical aortic valve replacement remains the standard 
of care for valvular intervention, with improvements 
in surgical and postoperative care driving periopera-
tive mortality down to ~1%–3%. Other important 
perioperative complications include conduction 
disease requiring permanent pacemaker insertion 
(1.5%–8.6%32) and cerebrovascular accidents (2.4%–
8.1%33–35). There is also the risk of cognitive decline 
(due to perioperative cerebral hypoperfusion micro-
emboli or anaesthetic agent neurotoxicity35). An indi-
vidual’s risk of these complications can be estimated 
using surgical risk calculators such as EUROSCORE II 
and the Society of Thoracic Surgeons score. An argu-
ment in favour of early surgery is that operative risk 
is lower in younger patients that are asymptomatic, 
have less comorbidity and have normal left ventric-
ular function.
The emergence of minimally invasive transcath-
eter aortic valve insertion (TAVI) over the last 10 
years has completely changed the landscape for 
decision making regarding valve intervention in 
symptomatic patients. Current trials show non-in-
feriority of this percutaneous technique compared 
with surgical intervention in both high-risk and 
intermediate-risk patients,34 36–39 and procedural 
risk may further reduce with increasing clinical 
experience and advances in prosthesis design and 
delivery. Indeed, major vascular complications have 
decreased substantially (from >10% to <5%40) as 
have stroke rates, which are between 2% and 3% 
in contemporary cohorts.40 However, the require-
ment for permanent cardiac pacing postprocedure 
remains consistently higher than surgical interven-
tion at >10%40 and while TAVI allows for rapid 
patient recovery and mobilisation, the long-term 
durability of these bioprostheses has not been 
demonstrated.41 This will be key before their 
widespread use in younger or asymptomatic patient 
groups can be recommended.
Performing valve intervention introduces small 
but significant annual risks associated with the pres-
ence of a prosthetic valve. These risks are heavily 
influenced by valve type, with both anticoagulant 
related major bleeding (1.8%–2.6% per year) and 
thromboembolism (0.7%–1.0% per year) more 
frequent with mechanical valves.42 In addition, there 
is an increased risk of endocarditis (1%–3% during 
the first year then <0.5% per year43), which has a 
high associated morbidity and mortality. Whereas 
structural valve degeneration is exceedingly rare 
in mechanical valves, bioprosthetic valves have a 
limited lifespan which can be difficult to predict. 
In these patients, valve degeneration usually starts 
to occur 10 years following implantation44 and 
occurs more rapidly in younger patients.45 This is 
an extremely important issue if bioprosthetic valves 
are to be used in younger asymptomatic patients. 
Ongoing research into decellularisation techniques 
and tissue engineering may lead to improved 
bioprosthetic valve longevity, while advances in 
mechanical valve design might eventually elimi-
nate the need for anticoagulation and associated 
bleeding risk. In addition, the use of a transcatheter 
valve inside a surgical bioprosthetic valve (so called 
valve-in-valve TAVI) may reduce the risk of future 
procedures should valve degeneration occur.
risks of not intervening
The risk of sudden cardiac death in patients with 
asymptomatic severe AS managed conservatively 
is ~1% per year and occurs without preceding symp-
toms in 70% of cases.46–48 Once symptoms develop, 
further clinical deterioration can be rapid with a 
significant risk of sudden death while awaiting inter-
vention (4% at 1 month, 12% at 6 months).49
Table 3 Estimates of clinical risks associated with watchful waiting or early intervention strategies 
risks associated with watchful waiting risk estimate risks associated with early intervention risk estimate
Sudden cardiac death 1.0%–1.5% per year
46–48
Perioperative mortality 1%–3%
(refine using validated risk calculator)
Death while awaiting elective intervention 
once symptoms develop
4% at 1 month, 12% at 6 months
49
Perioperative complications (SAVR):
 ► Stroke.
 ► Pacemaker requirement.
 ► Major bleeding.
 ► New atrial fibrillation.
 
2.4%–8.1%33–35
1.5%–8.6%32
9%–26%36 39
17%–43%34 36 39
Increased perioperative mortality:
 ► Impaired left ventricular function.
 ► No contractile reserve.
(Refine using validated risk calculator)
9%–19%10 20 50
22%–32%11 52
Periprocedural complications (TAVI):
 ► Stroke.
 ► Pacemaker requirement.
 ► Major vascular complications.
 ► Major bleeding.
 ► New atrial fibrillation.
 
2.2%–2.6%.40
7%–25%38–40
2.0%–4.5%40
12%–15%36 39
10%–13%34 36 39
Lack of improvement in ejection fraction 
following intervention
25%–50%10 11 Long-term prosthetic valve complications:
 ► Thromboembolism.
 ► Major bleeding with anticoagulation.
 
0.7%–1.0% per year42
1.8%–2.6% per year42
Incomplete resolution of symptoms Approximately 50%50 Prosthetic valve endocarditis 1%–3% in first year then <0.5% per year43
Increased late postintervention mortality:
 ► Impaired ejection fraction.
 ► Myocardial fibrosis.
HR 2.020
HR 1.25–5.2521 51 57
Reoperation for structural valve 
degeneration:
 ► <65 years of age.
 ► >65 years of age.
 
 
46%–55% at 20 years
8%–15% at 20 years45
SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.
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Delaying aortic valve intervention until there 
is evidence of advanced left ventricular decom-
pensation results in greater perioperative risks.48 
Observational studies have quoted increased 
perioperative mortality (9%–19%10 20 50) in patients 
who have developed left ventricular systolic impair-
ment and advanced myocardial fibrosis.51 Further 
risk stratification can be performed using stress 
echocardiography to assess myocardial contractile 
reserve, with lower perioperative risks if contractile 
reserve is present (5% vs 22%–32%11 52). However, 
given the dismal prognosis of untreated AS, even 
patients without contractile reserve have improved 
long-term survival if they survive the perioperative 
period.10 11
The highest burden in mortality and morbidity 
related to delaying valve intervention appears to 
occur in the months and years following AVR, 
particularly in those patients that have evidence 
of left ventricular decompensation. As discussed, 
patients with an impaired ejection fraction prior 
to AVR have a poor long-term prognosis,20 while 
in a recent study of AS patients with a high proba-
bility of LV decompensation, more than half were 
either dead or admitted to hospital with heart 
failure within 2 years.53 Both these observations 
may reflect the development of irreversible scarring 
in the myocardium while patients are waiting for 
surgery.
PossIBlE fuTurE sTraTEgIEs
Several different strategies for optimising the timing 
of valve replacement in AS have been proposed, 
many of which are currently being evaluated within 
the context of randomised controlled trials (figure 3 
and table 4). Many of these target asymptomatic 
patients, and it should be recognised that many 
patients that feel otherwise fit and healthy might 
not want to undergo major heart surgery.
all-comers with severe as
Historical teaching has been that ‘aortic valve 
replacement is the most common cause of death in 
patients with asymptomatic severe aortic stenosis’. 
However, improving outcomes following surgical 
and transcatheter valve replacement are challenging 
this doctrine. Performing valve intervention on all 
asymptomatic patients with severe AS is a simple 
and pragmatic solution that does not seek to iden-
tify the point at which left ventricular decompensa-
tion occurs. Although some patients will undergo 
intervention earlier than they may have required 
(and therefore be exposed unnecessarily to the 
problems associated with prosthetic valves), the 
risks associated with contemporary intervention 
techniques are low, and no patient should be left 
with irreversible left ventricular decompensation. 
This strategy is supported by evidence from the 
Japanese Contemporary outcomes after sURgery 
and medical tREatmeNT in patients with severe 
Aortic Stenosis (CURRENT AS) registry. Propensi-
ty-score matching was used to compare 291 asymp-
tomatic patients who underwent early surgery with 
291 patients who were managed conservatively. 
Those who received early AVR had a reduced 
all-cause mortality at 5 years (15%) compared 
figure 3 Comparison of EARLY-TAVR and EVoLVeD randomised controlled trial designs. Currently, recruiting randomised controlled trials generally 
fall into two groups: those investigating valve intervention in all asymptomatic patients with severe AS (eg, EARLY-TAVR) and those looking to target 
intervention based on measures of left ventricular decompensation (eg, EVoLVeD). AS, aortic stenosis; CMR, cardiac magnetic resonance; EARLY-TAVR, 
Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients with AsYmptomatic Severe Aortic Stenosis; EVoLVeD, 
Early Valve Replacement Guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients with Severe AS; hs, high-sensitivity; LV, 
left ventricular; TAVI, transcatheter aortic valve insertion.
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with those who were initially managed conserva-
tively (26%). Heart failure hospitalisation was also 
reduced in the early intervention group (4% vs 
20%). However, propensity matching may not have 
accounted for all potential influences on outcomes 
and a significant proportion of the conservatively 
managed patients who developed symptoms were 
not referred for intervention, undoubtedly contrib-
uting to the worse observed survival in this group: 
confounding by indication. Three randomised 
controlled trials (AVATAR, ESTIMATE and EARLY-
TAVR; table 4) are currently recruiting, which will 
examine whether valve intervention in unselected 
asymptomatic patients with severe AS can improve 
clinical outcomes.
refined assessment of valve structure and 
function
An alternative strategy is to operate only in asymp-
tomatic patients with very high peak aortic-jet 
velocities. Peak velocities >4.5 m/s are associated 
with increased referral for surgical intervention26 
but also increased rates of perioperative death 
and cardiac death in a prospective cohort study 
with propensity matching.47 The RECOVERY 
randomised controlled trial will examine whether 
early aortic valve replacement in asymptomatic 
patients with velocities >4.5 m/s and a negative 
exercise test leads to improved patient outcomes 
compared with watchful waiting (table 4).
The total haemodynamic load seen by the left 
ventricle can also be quantified by calculating the 
valvuloarterial impedence (ZVa=(systolic blood 
pressure+mean AV gradient)/indexed LV stroke 
volume). This measure has consistently been shown 
to be an independent marker of adverse outcome in 
asymptomatic patients54 and warrants further study 
for its use in determining the timing of intervention.
Another approach is to quantify valvular calcium 
burden using CT calcium scoring. Validated, 
sex-specific thresholds for severe AS have been 
proposed (2000 Agatston units (AU) for men, 
1200 AU for women),5 which provide powerful 
prediction of clinical events of incremental value to 
echocardiographic assessments.3 Performing valve 
intervention on the basis of severe valvular calcifi-
cation on CT might therefore represent an attrac-
tive alternative strategy.
Imaging and biomarkers of left ventricular 
decompensation
Simple cardiac biomarkers beyond BNP are being 
investigated in AS as markers of LV decompen-
sation. Cardiac troponin is a structural protein 
present in cardiomyocytes, which is released into 
the bloodstream during myocardial injury and can 
now be detected at very low plasma concentra-
tions using high-sensitivity assays. In AS, troponin I 
concentrations are associated with a more advanced 
left ventricular hypertrophic response, replace-
ment myocardial fibrosis and worse long-term 
patient outcomes in patients with AS.55 They are 
thought to reflect the cardiomyocyte death that 
drives progressive left ventricular decompensation 
alongside myocardial fibrosis.8 Elevation in cardiac 
troponin is not however specific to AS. By contrast, 
the presence of LVH and the strain pattern on the 
12-lead ECG demonstrate high specificity (but low 
sensitivity) for left ventricular hypertrophy and 
myocardial fibrosis, respectively, and also provides 
prognostic information.56 As will be discussed, 
there is interest in using these simple and cheap 
biomarkers as screening tools to aid the detection 
of LV decompensation (figure 4).
What about imaging assessment to detect left 
ventricular decompensation? Despite its limita-
tions, ejection fraction remains the current gold 
standard; however, several imaging techniques 
are under early investigation that can detect 
earlier abnormalities in left ventricular function. 
Table 4 Current and planned randomised controlled trials investigating timing of aortic valve intervention
strategy Proposed or ongoing trials Population Intervention Primary outcome
Trial status/
unique identifier Country
Estimated 
completion
All-comers with 
asymptomatic severe AS
Aortic Valve Replacement Versus 
Conservative Treatment in 
Asymptomatic Severe Aortic Stenosis 
(AVATAR)
312 patients with asymptomatic 
severe AS and STS score <8%.
SAVR or
routine care.
All-cause mortality and MACE 
at 3 years.
Recruiting 
NCT02436655
Serbia 2020
Early Surgery for Patients with 
Asymptomatic Aortic Stenosis 
(ESTIMATE)
360 patients with asymptomatic 
severe AS, normal ETT and low 
surgical risk.
SAVR or
routine care.
All-cause mortality and MACE 
at 1 year.
Recruiting
NCT02627391
France 2019
Evaluation of Transcatheter Aortic 
Valve Replacement Compared 
to SurveilLance for Patients with 
AsYmptomatic Severe Aortic 
Stenosis (EARLY-TAVR)
1109 patients aged >65 years with 
asymptomatic severe AS, trileaflet 
valve morphology and favourable 
ileofemoral arterial anatomy.
Transfemoral TAVI 
(Edwards SAPIEN 
3) or
routine care.
All-cause mortality, all stroke, 
and unplanned cardiovascular 
hospitalisation at 2 years.
Recruiting
NCT03042104
United 
States
2021
Refined assessment of 
valve function
– higher peak aortic-jet 
velocity threshold
Early Surgery Versus Conventional 
Treatment in Very Severe Aortic 
Stenosis (RECOVERY)
145 patients with very severe AS 
(Vmax >4.5 m/s, AVA <0.75 cm) and 
a negative ETT.
SAVR or
routine care.
Cardiac mortality at 4 years. Recruiting
NCT01161732
South 
Korea
2022
Assessment of myocardial 
decompensation
– multiple biomarker 
assessment of 
left ventricular 
decompensation
Early Valve Replacement Guided 
by Biomarkers of Left Ventricular 
Decompensation in Asymptomatic 
Patients with Severe AS (EVoLVeD)
400 patients with asymptomatic 
severe AS, normal LVEF and mid-wall 
fibrosis on cardiac MRI.
SAVR/TAVI or
routine care.
All-cause mortality and 
unplanned AS-related 
hospitalisation at 3 years.
Recruiting
NCT03094143
UK 2020
AS, aortic stenosis; ETT, exercise tolerance test; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular events; SAVR, surgical aortic valve replacement; STS, Society of Thoracic Surgeons; 
TAVI, transcatheter aortic valve insertion.
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Echocardiography can detect alteration in various 
measures of diastolic and longitudinal systolic 
function in patients with AS, which appear related 
to the presence of myocardial fibrosis.7 Reduced 
left ventricular global longitudinal strain can be 
observed in asymptomatic patients with AS, acting as 
an independent predictor of mortality.23 However, 
several of these measures still require standardisa-
tion across vendor platforms and all suffer from 
significant overlap between results in healthy indi-
viduals and those with AS. Moreover, these imaging 
markers are not specific to valve heart disease and 
like symptoms might equally reflect comorbidity 
such as ischaemic heart disease.
Perhaps the most promising technique is cardiac 
MRI, which offers myocardial tissue characteri-
sation and can detect the myocardial fibrosis that 
drives the development of left ventricular decom-
pensation. Indeed, the late gadolinium enhance-
ment technique allows direct visualisation of this 
fibrosis in a midwall pattern that can easily be 
differentiated from prior myocardial infarction. 
Midwall fibrosis is a direct and specific marker of 
left ventricular decompensation with close asso-
ciation with measures of left ventricular func-
tion, myocardial injury and functional capacity.7 
Furthermore, multiple studies have confirmed 
that midwall fibrosis is a strong independent 
predictor of all-cause mortality and cardiovascular 
death.21 51 57 Increasing burden of midwall fibrosis 
correlates with a worse outcome,21 51 and this 
fibrosis appears irreversible following valve inter-
vention.58 Midwall fibrosis therefore appears as a 
useful tool to identify the early stages of irrevers-
ible left ventricular decompensation. T1 mapping 
is an alternative technique that might allow detec-
tion of the preceding stage of reversible diffuse 
interstitial fibrosis.59 At present, there are issues 
with variations in T1 values at different magnetic 
field strengths and on different scanners and prob-
lems caused by the overlap of T1 values between 
different disease states. Further work is required, 
although recent studies have shown promising early 
results for T1 parameters that seek to measure the 
overall myocardial fibrosis volume.7
It is possible that using a multibiomarker strategy 
to identify LV decompensation may prove superior 
to any single biomarker in isolation. For example, in 
the EVoLVeD randomised controlled trial (table 4), 
patients are initially screened with high sensitivity 
troponin I and an ECG. Patients with a normal 
troponin (<6 ng/L) are deemed to have a normal 
heart with no further imaging required. Patients 
with an elevated troponin or the ECG-strain 
pattern proceed to cardiac magnetic resonance 
(CMR) and those found to have midwall fibrosis 
then randomised to either early valve intervention 
or routine clinical care. It is hoped that this strategy 
will target valve intervention to those patients who 
will derive greatest benefit.
PraCTICal rECoMMEndaTIons and 
ProCEssEs of CarE
Care of the asymptomatic patient with AS can 
be complex and challenging. While additional 
evidence is awaited, we advise detailed clinical and 
figure 4 Imaging and biomarker assessments of stage of valvular stenosis and myocardial response to increased afterload. Progressive 
haemodynamic obstruction as a result of aortic leaflet restriction is assessed using echocardiography. However, specific valvular pathologies such 
as fibrosis and calcification can be assessed using CT methods. Ejection fraction is a poorly sensitive marker of myocardial decompensation with 
abnormalities in Doppler measures, longitudinal strain and systolic function, which are all detectable prior to this. However, these measures, along 
with biomarkers such as troponin and B-type natriuretic peptide (BNP) are non-specific and may be abnormal as a result of coexistent myocardial 
pathology such as coronary heart disease. T1 mapping methods and late gadolinium enhancement are more specific for decompensation as a result of 
pressure overload.
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echocardiographic assessment with exercise testing 
and advanced imaging (eg, stress echocardiog-
raphy, TOE, CT and CMR) performed as indicated 
to clarify symptoms, severity of AS and myocar-
dial health. This should be performed by heart 
valve specialists working as part of a heart team.5 
Patient involvement in decision making is key 
where indications for intervention are borderline. 
Given delays between referral and procedure that 
are common in most healthcare systems, this could 
also be discussed with the patient and may inform 
decision making for earlier intervention. The recent 
ESC/EACTS guideline update also recommends the 
establishment of heart valve centres with access to 
advanced imaging modalities and contemporary 
interventional techniques supported by robust 
internal audit processes.5 Finally, patients managed 
conservatively should be educated as to the typical 
symptoms of AS (table 2) and the importance of 
prompt symptom reporting. Regular clinic surveil-
lance is essential, and current guidelines recom-
mend clinical assessment with echocardiography at 
least every 6 months.5
ConClusIons
AS is a common condition; the only treatment 
for which is replacement of the aortic valve. The 
optimal timing of this valve intervention remains 
unclear with current guidelines based on obser-
vational data and expert opinion. However, 
multiple randomised controlled trials are currently 
underway investigating whether novel strategies 
might improve patient outcomes compared with 
current watchful waiting, heralding a new era of 
evidence-based medicine for patients with heart 
valve disease.
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